R-CHMP regimen
WikiDoc Resources for R-CHMP regimen |
Articles |
---|
Most recent articles on R-CHMP regimen Most cited articles on R-CHMP regimen |
Media |
Powerpoint slides on R-CHMP regimen |
Evidence Based Medicine |
Clinical Trials |
Ongoing Trials on R-CHMP regimen at Clinical Trials.gov Trial results on R-CHMP regimen Clinical Trials on R-CHMP regimen at Google
|
Guidelines / Policies / Govt |
US National Guidelines Clearinghouse on R-CHMP regimen NICE Guidance on R-CHMP regimen
|
Books |
News |
Commentary |
Definitions |
Patient Resources / Community |
Patient resources on R-CHMP regimen Discussion groups on R-CHMP regimen Patient Handouts on R-CHMP regimen Directions to Hospitals Treating R-CHMP regimen Risk calculators and risk factors for R-CHMP regimen
|
Healthcare Provider Resources |
Causes & Risk Factors for R-CHMP regimen |
Continuing Medical Education (CME) |
International |
|
Business |
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aparna Vuppala, M.B.B.S. [2]
Synonyms and keywords: Rituximab-Cyclophosphamide-Hydroxydaunorubicin-Marqibo-Prednisone regimen
Overview
R-CHMP regimen refers to a regimen consisting of rituximab, cyclophosphamide , doxorubicin (hydroxydaunorubicin), vincristine (Marqibo), and prednisone used to treat aggressive non-Hodgkin's lymphoma.[1]
Regimen
RRituximab (Rituxan)
CCyclophosphamide (Cytoxan)
HDoxorubicin (Hydroxydaunorubicin)
MVincristine liposomal (Marqibo)
PPrednisone
Indications
References
- ↑ 1.0 1.1 Hagemeister F, Rodriguez MA, Deitcher SR, Younes A, Fayad L, Goy A; et al. (2013). "Long term results of a phase 2 study of vincristine sulfate liposome injection (Marqibo(®) ) substituted for non-liposomal vincristine in cyclophosphamide, doxorubicin, vincristine, prednisone with or without rituximab for patients with untreated aggressive non-Hodgkin lymphomas". Br J Haematol. 162 (5): 631–8. doi:10.1111/bjh.12446. PMID 23802738.